Nitto-denko Corporation

Nagoya University

Kenjiro Minomi

Yoshiro Niitsu

Yasunobu Tanaka

Elena Feinstein

Wenbin Ying

Joseph E Payne

Igor Mett

Hagar Kalinski

Mohammad Ahmadian

Richard P Witte

Victor Knopov

Violetta Akopian

Loren A Perelman

Yun Liu

Sharon Avkin-Nahum

Lei Yu

Mitsuhiko Hori

Kenjiro Mori

Zheng Hou

Masaki Tsukamoto

Hiroyuki Tanaka

Tatsuya Konishi

Lisbeth Illum

Yoshihisa Nakano

Eri Maeta

Erika Terada

Yoshihiro Hayakawa

Priya Prakash Karmali

Yusuke Nakashima

John Gaudette

Kensuke Matsuoka

Katsuyuki Okubo

Hirokazu Takahashi

Jian Liu

Chieko Kitaura

Sridhar C Nagarajan

Keisaku Okada

Naoko Urushihara

Rishu Takimoto

Yucheng Song

Elizabeth Pearson

Snjezana Stolnik-Trenkic

Masashi Kamiyama

Natsuko Kagehisa

Keiko Kajiwara

Miyono Miyazaki

Noritaka Suzuki

Sharon Avkin-nachum

Kiminori Nakamura

Yun Lui

Martyn C Davies

Toshihiko Okazaki

The present invention provides a nucleic acid molecule dimer that includes a first nucleic acid molecule having complementarity with at least part of a target nucleic acid molecule, and a second nucleic acid molecule having complementarity with the first nucleic acid molecule, wherein the first nucleic acid molecule has a linear form, the second nucleic acid molecule has a cyclic form, and the first and second nucleic acid molecules at least partially form a double strand.

Regulation of nucleic acid molecule expression

What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier

What is described is a pharmaceutical composition for treating a fibrotic disease comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Retinoid-lipid drug carrier

Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targetability to peptide (1), and (3) a peptide mimetic having a comparable targetability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.

Targeting molecule and a use thereof

The invention provides a universal linker capable of synthesizing nucleic acid having a hydroxy group at the 3' terminal, a universal support carrying the linker, and a synthesis method of nucleic acid using the universal support. The linker contains a compound represented by the formula wherein each symbol is as defined in the specification.

Linker and support for solid phase synthesis of nucleic acid

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 expression, including fibrosis.

Retinoid-liposomes for treating fibrosis

The invention provides a universal linker capable of synthesizing nucleic acid having a phosphate group at the 3' terminal, a universal support carrying the linker, and a synthesis method of nucleic acid using the universal support. The linker for solid phase synthesis of nucleic acid contains a compound represented by at least one of the following formulae wherein each symbol is as defined in the specification.

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH(SEQ ID NOS: 60 and 127), SERPINH(SEQ ID NOS: 98 and 165), and SERPINH(SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.

Retinoid-liposomes for enhancing modulation of HSP47 expression

Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent.

Therapeutic agent for pulmonary fibrosis

Methods and kits for transporting heterologous compounds into cells, particularly mammalian cells, are disclosed. The method involves the pretreatment of the cell with a polycation, cationic polymer and/or cationic peptide before transportation of the heterologous compound into the cell. The methods are particularly applicable to the transport of peptides and proteins.

Methods of intracellular peptide delivery

Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.

Transepithelial delivery of peptides with incretin hormone activities

A percutaneously absorptive preparation is provided, which preparation having a support and an adhesive layer having a release-controlling layer, which is formed at least on one side of the support, wherein the adhesive layer contains an adhesive and 0.5&#x2013;60 wt % of a drug except 1,2-ethanediol derivatives.

Percutaneously absorptive preparation

The present invention provides a percutaneous absorption preparation which comprises a skin contact base containing therein at least one active ingredient selected from the group consisting of biperiden, trihexyphenidyl and pharmacologically acceptable salts thereof in an amount of from 0.5 to 60% by weight. The percutaneous absorption preparation makes it possible to permit the percutaneous absorption of biperiden, trihexyphenidyl or pharmacologically acceptable salt thereof as an active ingredient so that the medicament can be used effectively and at the same time, pharmacological effects can be sustained long and administration can be carried out conveniently. In addition, the active ingredient contained in it can be maintained stably.

Percutaneous absorption preparation

Growing community of inventors

Osaka, Japan

Kenjiro Minomi